Article Text

Download PDFPDF

Immunotherapy targeting esophageal cancer stem cells
  1. Dongli Yue1,2,
  2. Hongzheng Ren1,3,
  3. Lan Huang1,2 and
  4. Yi Zhang1,2
  1. Aff1 grid.412633.1The Biotherapy CenterThe First Affiliated Hospital of Zhengzhou University Zhengzhou China
  2. Aff2 grid.412633.1The Department of OncologyThe First Affiliated Hospital of Zhengzhou University Zhengzhou China
  3. Aff3 grid.256922.8000000009139560XThe Department of OncologyThe Center Hospital of Kaifeng, Henan University Kaifeng China

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts

Esophageal cancer is one of most common malignancies. Cancer stem cells (CSC) are considered to be resistant to chemotherapy and radiotherapy, which might be associated with the recurrence of the tumor after treatment. To find the therapeutic procedures targeting CSCs, the different methods have been used to identify the esophageal CSC-related genes and surface markers. The esophageal CSCs were found to resist the chemotherapy and the mechanism was explored as well. We also found the levels of tumor associated antigens in esophageal CSCs have differences comparing with the non-stem cancer cells. To understand if the tumor associated antigens can be used as targets by immune cells, we cloned the tumor antigen specific T cells and analyzed the T cell recognition of esophageal CSC both in vitro and in vivo. We found that the immunotherapy might be one of the optimal procedures targeting both non-stem cancer cells and esophageal CSC.